The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
WNT signalling in prostate cancer
Abstract
Genome sequencing and gene expression analyses of prostate tumours have highlighted the potential importance of genetic and epigenetic changes observed in WNT signalling pathway components in prostate tumours — particularly in the development of castration-resistant prostate cancer. WNT signalling is also important in the prostate tumour microenvironment, in which WNT proteins secreted by the tumour stroma promote resistance to therapy, and in prostate cancer stem or progenitor cells, in which WNT–β-catenin signals promote self-renewal or expansion. Preclinical studies have demonstrated the potential of inhibitors that target WNT receptor complexes at the cell membrane or that block the interaction of β-catenin with lymphoid enhancer-binding factor 1 and the androgen receptor, in preventing prostate cancer progression. Some WNT signalling inhibitors are in phase I trials, but they have yet to be tested in patients with prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sun, Y., Zhu, D., Chen, F., Qian, M., Wei, H., Chen, W., & Xu, J. (2016) · Oncogene · doi:10.1038/onc.2015.494 · Cited by 122
RetractedSiegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Wnt/β-Catenin Signaling in Development and Disease
Clevers, H. (2006) · Cell · doi:10.1016/j.cell.2006.10.018 · Cited by 5,568
The Wnt Signaling Pathway in Development and Disease
Logan, C. Y., & Nusse, R. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.113126 · Cited by 5,325
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.003 · Cited by 3,227
Polakis, P. (2000) · Genes & Development · doi:10.1101/gad.14.15.1837 · Cited by 3,183
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
AP-1: a double-edged sword in tumorigenesis
Eferl, R., & Wagner, E. F. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1209 · Cited by 2,242
WNT signalling pathways as therapeutic targets in cancer
Anastas, J. N., & Moon, R. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3419 · Cited by 1,911
The Biology of YAP/TAZ: Hippo Signaling and Beyond
Piccolo, S., Dupont, S., & Cordenonsi, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00005.2014 · Cited by 1,802
Wnt signalling and its impact on development and cancer
Klaus, A., & Birchmeier, W. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2389 · Cited by 1,595
Secreted antagonists of the Wnt signalling pathway
Kawano, Y., & Kypta, R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00623 · Cited by 1,584
Self-citationEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Wnt signal transduction pathways
Komiya, Y., & Habas, R. (2008) · Organogenesis · doi:10.4161/org.4.2.5851 · Cited by 1,528
The complex world of WNT receptor signalling
Niehrs, C. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3470 · Cited by 1,492
Small molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer
Chen, B., Dodge, M. E., Tang, W., Lu, J., Ma, Z., Fan, C.-W., Wei, S., Hao, W., Kilgore, J., Williams, N. S., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.137 · Cited by 1,383
Veeman, M. T., Axelrod, J. D., & Moon, R. T. (2003) · Developmental Cell · doi:10.1016/s1534-5807(03)00266-1 · Cited by 1,359
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
Takebe, N., Miele, L., Harris, P. J., Jeong, W., Bando, H., Kahn, M., Yang, S. X., & Ivy, S. P. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.61 · Cited by 1,298
YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response
Azzolin, L., Panciera, T., Soligo, S., Enzo, E., Bicciato, S., Dupont, S., Bresolin, S., Frasson, C., Basso, G., Guzzardo, V., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.013 · Cited by 1,094
Can we safely target the WNT pathway?
Kahn, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4233 · Cited by 1,034
ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner
Hao, H.-X., Xie, Y., Zhang, Y., Charlat, O., Oster, E., Avello, M., Lei, H., Mickanin, C., Liu, D., Ruffner, H., et al. (2012) · Nature · doi:10.1038/nature11019 · Cited by 972
Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk
Chornokur, G., Lin, H.-Y., Tyrer, J. P., Lawrenson, K., Dennis, J., Amankwah, E. K., Qu, X., Tsai, Y.-Y., Jim, H. S. L., Chen, Z., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128106 · Cited by 902
Structural Basis of Wnt Recognition by Frizzled
Janda, C. Y., Waghray, D., Levin, A. M., Thomas, C., & Garcia, K. C. (2012) · Science · doi:10.1126/science.1222879 · Cited by 875
Heidenreich, A., Bellmunt, J., Bolla, M., Joniau, S., Matveev, V. B., Mottet, N., Wiegel, T., & Zattoni, F. (2013) · Cited by 875
A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription
Emami, K. H., Nguyen, C., Ma, H., Kim, D. H., Jeong, K. W., Eguchi, M., Moon, R. T., Teo, J.-L., Oh, S. W., Kim, H. Y., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404875101 · Cited by 874
Leaders in Social Networks, the Delicious Case
Lü, L., Zhang, Y.-C., Yeung, C. H., & Zhou, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021202 · Cited by 871
Karantanos, T., Corn, P. G., & Thompson, T. C. (2013) · Oncogene · doi:10.1038/onc.2013.206 · Cited by 866
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
Liu, J., Pan, S., Hsieh, M. H., Ng, N., Sun, F., Wang, T., Kasibhatla, S., Schuller, A. G., Li, A. G., Cheng, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314239110 · Cited by 831
Sun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., True, L., & Nelson, P. S. (2012) · Nature Medicine · doi:10.1038/nm.2890 · Cited by 793
Wnt and calcium signaling: β-Catenin-independent pathways
Kohn, A. D., & Moon, R. T. (2005) · Cell Calcium · doi:10.1016/j.ceca.2005.06.022 · Cited by 730
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance
Miyamoto, D. T., Zheng, Y., Wittner, B. S., Lee, R. J., Zhu, H., Broderick, K. T., Desai, R., Fox, D. B., Brannigan, B. W., Trautwein, J., et al. (2015) · Science · doi:10.1126/science.aab0917 · Cited by 705
Alternative Wnt Signaling Activates YAP/TAZ
Park, H. W., Kim, Y. C., Yu, B., Moroishi, T., Mo, J.-S., Plouffe, S. W., Meng, Z., Lin, K. C., Yu, F.-X., Alexander, C. M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.013 · Cited by 705
Bovolenta, P., Esteve, P., Ruiz, J. M., Cisneros, E., & Lopez-Rios, J. (2008) · Journal of Cell Science · doi:10.1242/jcs.026096 · Cited by 655
Secreted and transmembrane wnt inhibitors and activators
Cruciat, C.-M., & Niehrs, C. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a015081 · Cited by 646
Gurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614
Frizzled and LRP5/6 Receptors for Wnt/ -Catenin Signaling
MacDonald, B. T., & He, X. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007880 · Cited by 612
The Hippo Pathway Regulates Wnt/β-Catenin Signaling
Varelas, X., Miller, B. W., Sopko, R., Song, S., Gregorieff, A., Fellouse, F. A., Sakuma, R., Pawson, T., Hunziker, W., McNeill, H., et al. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.03.007 · Cited by 569
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · PubMed · doi:10.3978/j.issn.2223-4683.2015.05.02 · Cited by 514
Beltran, H., Yelensky, R., Frampton, G. M., Park, K., Downing, S. R., MacDonald, T. Y., Jarosz, M., Lipson, D., Tagawa, S. T., Nanus, D. M., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.08.053 · Cited by 454
TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion
Perner, S., Mosquera, J.-M., Demichelis, F., Hofer, M. D., Paris, P. L., Simko, J., Collins, C., Bismar, T. A., Chinnaiyan, A. M., De Marzo, A. M., et al. (2007) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213424.38503.aa · Cited by 426
Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma
Jiang, X., Hao, H.-X., Growney, J. D., Woolfenden, S., Bottiglio, C., Ng, N., Lu, B., Hsieh, M. H., Bagdasarian, L., Meyer, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307218110 · Cited by 414
Alternative Wnt Signaling Is Initiated by Distinct Receptors
van Amerongen, R., Mikels, A., & Nusse, R. (2008) · Science Signaling · doi:10.1126/scisignal.135re9 · Cited by 401
Proffitt, K. D., Madan, B., Ke, Z., Pendharkar, V., Ding, L., Lee, M. A., Hannoush, R. N., & Virshup, D. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2258 · Cited by 382
NFAT proteins: emerging roles in cancer progression
Mancini, M., & Toker, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2735 · Cited by 371
Wnts as ligands: processing, secretion and reception
Mikels, A. J., & Nusse, R. (2006) · Oncogene · doi:10.1038/sj.onc.1210053 · Cited by 356
A Noncanonical Frizzled2 Pathway Regulates Epithelial-Mesenchymal Transition and Metastasis
Gujral, T. S., Chan, M., Peshkin, L., Sorger, P. K., Kirschner, M. W., & MacBeath, G. (2014) · Cell · doi:10.1016/j.cell.2014.10.032 · Cited by 350
Liu, C., Lou, W., Zhu, Y., Nadiminty, N., Schwartz, C. T., Evans, C. P., & Gao, A. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3296 · Cited by 348
Wnt addiction of genetically defined cancers reversed by PORCN inhibition
Madan, B., Ke, Z., Harmston, N., Ho, S. Y., Frois, A. O., Alam, J., Jeyaraj, D. A., Pendharkar, V, Ghosh, K., Virshup, I. H., et al. (2016) · Oncogene · doi:10.1038/onc.2015.280 · Cited by 341
Gonsalves, F. C., Klein, K., Carson, B. B., Katz, S., Ekas, L. A., Evans, S., Nagourney, R., Cardozo, T., Brown, A. M. C., & DasGupta, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017496108 · Cited by 337
Weischenfeldt, J., Simon, R., Feuerbach, L., Schlangen, K., Weichenhan, D., Minner, S., Wuttig, D., Warnatz, H.-J., Stehr, H., Rausch, T., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.002 · Cited by 320
Bisson, I., & Prowse, D. M. (2009) · Cell Research · doi:10.1038/cr.2009.43 · Cited by 308
Steinhart, Z., Pavlovic, Z., Chandrashekhar, M., Hart, T., Wang, X., Zhang, X., Robitaille, M., Brown, K. R., Jaksani, S., Overmeer, R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4219 · Cited by 297
Chen, G., Shukeir, N., Potti, A., Sircar, K., Aprikian, A., Goltzman, D., & Rabbani, S. A. (2004) · Cancer · doi:10.1002/cncr.20518 · Cited by 283
Gupta, S., Iljin, K., Sara, H., Mpindi, J. P., Mirtti, T., Vainio, P., Rantala, J., Alanen, K., Nees, M., & Kallioniemi, O. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0244 · Cited by 278
Wnt/β-catenin signalling in prostate cancer
Kypta, R. M., & Waxman, J. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.116 · Cited by 275
Self-citationTargeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28
Le, P. N., McDermott, J. D., & Jimeno, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.08.005 · Cited by 253
Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function
Storm, E. E., Durinck, S., de Sousa e Melo, F., Tremayne, J., Kljavin, N., Tan, C., Ye, X., Chiu, C., Pham, T., Hongo, J.-A., et al. (2016) · Nature · doi:10.1038/nature16466 · Cited by 249
Chen, C., Mahalingam, D., Osmulski, P., Jadhav, R. R., Wang, C., Leach, R. J., Chang, T., Weitman, S. D., Kumar, A. P., Sun, L., et al. (2013) · The Prostate · doi:10.1002/pros.22625 · Cited by 239
The molecular and cellular origin of human prostate cancer
Packer, J. R., & Maitland, N. J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.02.016 · Cited by 239
International Union of Basic and Clinical Pharmacology. LXXX. The Class Frizzled Receptors
Schulte, G. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.002931 · Cited by 231
Lu, W., Lin, C., Roberts, M. J., Waud, W. R., Piazza, G. A., & Li, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029290 · Cited by 230
Yamamoto, H., Oue, N., Sato, A., Hasegawa, Y., Yamamoto, H., Matsubara, A., Yasui, W., & Kikuchi, A. (2010) · Oncogene · doi:10.1038/onc.2009.496 · Cited by 228
Current Management of Castrate-Resistant Prostate Cancer
Hotte, S. J., & Saad, F. (2010) · Current Oncology · doi:10.3747/co.v17i0.718 · Cited by 227
Mitotic Wnt Signaling Promotes Protein Stabilization and Regulates Cell Size
Acebron, S. P., Karaulanov, E., Berger, B. S., Huang, Y.-L., & Niehrs, C. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.04.014 · Cited by 225
Alternative Wnt Pathways and Receptors
van Amerongen, R. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007914 · Cited by 225
Cojoc, M., Peitzsch, C., Kurth, I., Trautmann, F., Kunz-Schughart, L. A., Telegeev, G. D., Stakhovsky, E. A., Walker, J. R., Simin, K., Lyle, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1924 · Cited by 223
The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers
Zhang, S., Chen, L., Wang-Rodriguez, J., Zhang, L., Cui, B., Frankel, W., Wu, R., & Kipps, T. J. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.08.024 · Cited by 207
Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins
Wang, W., Li, N., Li, X., Tran, M. K., Han, X., & Chen, J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.014 · Cited by 206
Discovery and Characterization of a Small Molecule Inhibitor of the PDZ Domain of Dishevelled
Grandy, D., Shan, J., Zhang, X., Rao, S., Akunuru, S., Li, H., Zhang, Y., Alpatov, I., Zhang, X. A., Lang, R. A., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.009647 · Cited by 201
Kitajima, K., Murphy, R. C., Nathan, M. A., Froemming, A. T., Hagen, C. E., Takahashi, N., & Kawashima, A. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.123018 · Cited by 200
The Role of Ryk and Ror Receptor Tyrosine Kinases in Wnt Signal Transduction
Green, J., Nusse, R., & van Amerongen, R. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009175 · Cited by 196
Fang, L., Zhu, Q., Neuenschwander, M., Specker, E., Wulf-Goldenberg, A., Weis, W. I., von Kries, J. P., & Birchmeier, W. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1519 · Cited by 190
CKAP4 is a Dickkopf1 receptor and is involved in tumor progression
Kimura, H., Fumoto, K., Shojima, K., Nojima, S., Osugi, Y., Tomihara, H., Eguchi, H., Shintani, Y., Endo, H., Inoue, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84658 · Cited by 188
Androgens and androgen receptor signaling in prostate tumorigenesis
Zhou, Y., Bolton, E. C., & Jones, J. O. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0203 · Cited by 183
Dijksterhuis, J. P., Petersen, J., & Schulte, G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12364 · Cited by 182
Tankyrases: Structure, Function and Therapeutic Implications in Cancer
Haikarainen, T., Krauss, S., & Lehtio, L. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140630101525 · Cited by 182
Replication Clamps and Clamp Loaders
Hedglin, M., Kumar, R., & Benkovic, S. J. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a010165 · Cited by 177
β-Catenin-Independent Roles of Wnt/LRP6 Signaling
Acebron, S. P., & Niehrs, C. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.07.009 · Cited by 175
Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells
Uysal-Onganer, P., Kawano, Y., Caro, M., Walker, M. M., Diez, S., Darrington, R. S., Waxman, J., & Kypta, R. M. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-55 · Cited by 171
Self-citationHao, H.-X., Jiang, X., & Cong, F. (2016) · Cancers · doi:10.3390/cancers8060054 · Cited by 171
Targeting the Wnt pathway in cancer: The emerging role of Dickkopf-3
Veeck, J., & Dahl, E. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.09.003 · Cited by 170
SOX9 drives WNT pathway activation in prostate cancer
Ma, F., Ye, H., He, H. H., Gerrin, S. J., Chen, S., Tanenbaum, B. A., Cai, C., Sowalsky, A. G., He, L., Wang, H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci78815 · Cited by 169
Crosstalk between the Androgen Receptor and β-Catenin in Castrate-Resistant Prostate Cancer
Wang, G., Wang, J., & Sadar, M. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1718 · Cited by 168
ROR1, an embryonic protein with an emerging role in cancer biology
Borcherding, N., Kusner, D., Liu, G.-H., & Zhang, W. (2014) · Protein & Cell · doi:10.1007/s13238-014-0059-7 · Cited by 159
Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy
Rajan, P., Sudbery, I. M., Villasevil, M. E. M., Mui, E. J., Fleming, J., Davis, M., Ahmad, I., Edwards, J., Sansom, O. J., Sims, D., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.08.011 · Cited by 159
Prostate tumor progression is mediated by a paracrine TGF-β/Wnt3a signaling axis
Li, X., Placencio, V. R., Iturregui, J. M., Uwamariya, C., Sharif‐Afshar, A., Koyama, T., Hayward, S. W., & Bhowmick, N. A. (2008) · Oncogene · doi:10.1038/onc.2008.293 · Cited by 159
Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., Cain, J., Tam, R., Cheng, C.-Y., Evans, J., et al. (2017) · Science Advances · doi:10.1126/sciadv.1700090 · Cited by 157
Brase, J. C., Johannes, M., Mannsperger, H., Fälth, M., Metzger, J., Kacprzyk, L. A., Andrasiuk, T., Gade, S., Meister, M. A., Sirma, H., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-507 · Cited by 156
Tumor–stroma co-evolution in prostate cancer progression and metastasis
Josson, S., Matsuoka, Y., Chung, L. W. K., Zhau, H. E., & Wang, R. (2009) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2009.11.016 · Cited by 141
Yee, D. S., Tang, Y., Li, X., Liu, Z., Guo, Y., Ghaffar, S., McQueen, P., Dash, A., Xie, J., Simoneau, A. R., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-162 · Cited by 136
The many roles of PTK7: A versatile regulator of cell–cell communication
Peradziryi, H., Tolwinski, N. S., & Borchers, A. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2011.12.019 · Cited by 129
Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN degradation and tumor growthPreprint
Li, N., Zhang, Y., Han, X., Liang, K., Wang, J., Feng, L., Wang, W., Songyang, Z., Lin, C., Yang, L., et al. (2014) · Genes & Development · doi:10.1101/gad.251785.114 · Cited by 127
Thudi, N. K., Martin, C. K., Murahari, S., Shu, S. T., Lanigan, L. G., Werbeck, J. L., Keller, E. T., McCauley, L. K., Pinzone, J. J., & Rosol, T. J. (2010) · The Prostate · doi:10.1002/pros.21277 · Cited by 126
Shultz, M. D., Cheung, A. K., Kirby, C. A., Firestone, B., Fan, J., Chen, C. H.-T., Chen, Z., Chin, D. N., DiPietro, L., Fazal, A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400807n · Cited by 126
A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.
El-Khoueiry, A. B., Ning, Y., Yang, D., Cole, S., Kahn, M. R., Zoghbi, M., Berg, J., Fujimori, M., Inada, T., Kouji, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2501 · Cited by 125
Säfholm, A., Tuomela, J. M., Rosenkvist, J., Dejmek, J. S., Härkönen, P. L., & Andersson, T. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0711 · Cited by 124
Lü, W., & Li, Y. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24850 · Cited by 123
Targeting Wnts at the Source—New Mechanisms, New Biomarkers, New Drugs
Madan, B., & Virshup, D. M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1038 · Cited by 122
Nile, A. H., Mukund, S., Stanger, K., Wang, W., & Hannoush, R. N. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618293114 · Cited by 118
Säfholm, A., Leandersson, K., Dejmek, J. S., Nielsen, C. K., Villoutreix, B. O., & Andersson, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508386200 · Cited by 117
Analysis of Wnt Gene Expression in Prostate Cancer
Zhu, H., Mazor, M., Kawano, Y., Walker, M. M., Leung, H. Y., Armstrong, K., Waxman, J., & Kypta, R. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2704 · Cited by 115
Self-citationRor2 as a Therapeutic Target in Cancer
Debebe, Z., & Rathmell, W. K. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.010 · Cited by 113
Martinez, S., Scerbo, P., Giordano, M., Daulat, A. M., Lhoumeau, A., Thomé, V., Kodjabachian, L., & Borg, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.697615 · Cited by 113
Li, Y., Wang, L., Zhang, M., Melamed, J., Liu, X., Reiter, R. E., Wei, J., Peng, Y., Zou, X., Pellicer, À., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3380 · Cited by 111
Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study
Vidal, A. C., Howard, L. E., Moreira, D. M., Castro‐Santamaria, R., Andriole, G. L., & Freedland, S. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2235 · Cited by 110
Extracellular modulators of Wnt signalling
Malinauskas, T., & Jones, E. Y. (2014) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2014.10.003 · Cited by 109
Terry, S., Yang, X., Chen, M., Vacherot, F., & Buttyan, R. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20983 · Cited by 107
Inhibition of androgen receptor and β-catenin activity in prostate cancer
Lee, E., Madar, A., David, G., Garabedian, M. J., DasGupta, R., & Logan, S. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218168110 · Cited by 106
Liu, C., Armstrong, C. M., Zhu, Y., Lou, W., & Gao, A. C. (2016) · Oncotarget · doi:10.18632/oncotarget.8493 · Cited by 104
Francis, J. C., Thomsen, M. K., Taketo, M. M., & Swain, A. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003180 · Cited by 100
Frizzled7: A Promising Achilles’ Heel for Targeting the Wnt Receptor Complex to Treat Cancer
Phesse, T. J., Flanagan, D. J., & Vincan, E. (2016) · Cancers · doi:10.3390/cancers8050050 · Cited by 98
ERG Is a Critical Regulator of Wnt/LEF1 Signaling in Prostate Cancer
Wu, L., Zhao, J. C., Kim, J., Jin, H., Wang, C.-Y., & Yu, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0882 · Cited by 97
Structure-Based Discovery of a Novel Inhibitor Targeting the β-Catenin/Tcf4 Interaction
Wang, T., Han, X., Yan, M., Xu, Y., Duggineni, S., Lin, N., Luo, G., Li, Y. M., Han, X., Huang, Z., et al. (2011) · Biochemistry · doi:10.1021/bi201428h · Cited by 93
Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer
Yun, E.-J., Zhou, J., Lin, C., Hernández, E., Fazli, L., Gleave, M. E., & Hsieh, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0190 · Cited by 93
Zong, Y., Huang, J., Sankarasharma, D., Morikawa, T., Fukayama, M., Epstein, J. I., Chada, K. K., & Witte, O. N. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217982109 · Cited by 91
SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation
Bilir, B., Osunkoya, A. O., Wiles, W. G., Sannigrahi, S., Lefebvre, V., METZGER, D., Spyropoulos, D. D., Martin, W. D., & Moreno, C. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1868 · Cited by 86
Wnt11 in 2011 – the regulation and function of a non‐canonical Wnt
Onganer, P. U., & Kypta, R. M. (2011) · Acta Physiologica · doi:10.1111/j.1748-1716.2011.02297.x · Cited by 83
Self-citationMallinger, A., Crumpler, S., Pichowicz, M., Waalboer, D., Stubbs, M., Adeniji-Popoola, O., Wood, B., Smith, E. L., Thai, C., Henley, A. T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501436m · Cited by 83
Hanaki, H., Yamamoto, H., Sakane, H., Matsumoto, S., Ohdan, H., Sato, A., & Kikuchi, A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0682 · Cited by 82
Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10
Fukukawa, C., Hanaoka, H., Nagayama, S., Tsunoda, T., Toguchida, J., Endo, K., Nakamura, Y., & Katagiri, T. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00701.x · Cited by 82
New insights into prostate cancer stem cells
Chen, X., Rycaj, K., Liu, X., & Tang, D. G. (2013) · Cell Cycle · doi:10.4161/cc.23721 · Cited by 80
de la Roche, M., Ibrahim, A. E. K., Mieszczanek, J., & Bienz, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2682 · Cited by 76
Selective Small Molecule Targeting β-Catenin Function Discovered by In Vivo Chemical Genetic Screen
Hao, J., Ao, A. S., Zhou, L., Murphy, C. K., Frist, A. Y., Keel, J., Thorne, C. A., Kim, K., Lee, E. N., & Hong, C. C. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.047 · Cited by 76
Role of WNT7B-induced Noncanonical Pathway in Advanced Prostate Cancer
Zheng, D., Decker, K. F., Zhou, T., Chen, J., Qi, Z., Jacobs, K., Weilbaecher, K. N., Corey, E., Long, F., & Li, J. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0520 · Cited by 75
Wnt signaling in castration-resistant prostate cancer: implications for therapy.
Yokoyama, N. N., Shao, S., Hoang, B. H., Mercola, D., & Zi, X. (2014) · PubMed · Cited by 75
Wnt5a promotes Frizzled-4 signalosome assembly by stabilizing cysteine-rich domain dimerizationPreprint
DeBruine, Z. J., Ke, J., Harikumar, K. G., Gu, X., Borowsky, P., Williams, B. O., Xu, W., Miller, L. J., Xu, H. E., & Melcher, K. (2017) · Genes & Development · doi:10.1101/gad.298331.117 · Cited by 71
Shojima, K., Sato, A., Hanaki, H., Tsujimoto, I., Nakamura, M., Hattori, K., Sato, Y., Dohi, K., Hirata, M., Yamamoto, H., et al. (2015) · Scientific Reports · doi:10.1038/srep08042 · Cited by 69
Li, Z. G., Yang, J., Vazquez, E. S., Rose, D., Vakar‐Lopez, F., Mathew, P. F., López, A., Logothetis, C. J., Lin, S.-H., & Navone, N. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210694 · Cited by 69
A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers
Ahmed, K., Shaw, H., Koval, A., & Katanaev, V. L. (2016) · Cancers · doi:10.3390/cancers8070066 · Cited by 66
A novel non-canonical Wnt signature for prostate cancer aggressiveness
Sandsmark, E., Hansen, A. F., Selnæs, K. M., Bertilsson, H., Bofin, A. M., Wright, A. J., Viset, T., Richardsen, E. H., Drabløs, F., Bathen, T. F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14161 · Cited by 66
Lee, G. T., Kang, D. I., Ha, Y.-S., Jung, Y. S., Chung, J. M., Min, K. S., Kim, T. H., Moon, K. H., Chung, J. M., Lee, D. H., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.23 · Cited by 65
CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer
Bordonaro, M., & Lazarova, D. L. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i27.8238 · Cited by 60
Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates
Thiele, S., Rauner, M., Goettsch, C., Rachner, T. D., Benad, P., Fuessel, S., Erdmann, K., Hamann, C., Baretton, G. B., Wirth, M. P., et al. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23070 · Cited by 55
Khaja, A. S. S., Helczynski, L., Edsjö, A., Ehrnström, R. A., Lindgren, A., Ulmert, D., Andersson, T., & Bjartell, A. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026539 · Cited by 52
Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells
Lee, E., Ha, S., & Logan, S. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141589 · Cited by 52
Takahashi, S., Watanabe, T., Okada, M., Inoue, K., Ueda, T., Takada, I., Watabe, T., Yamamoto, Y., Fukuda, T., Nakamura, T., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014850108 · Cited by 51
WNT5A Has Anti-Prostate Cancer Effects In Vitro and Reduces Tumor Growth in the Skeleton In Vivo
Thiele, S., Göbel, A., Rachner, T. D., Fuessel, S., Froehner, M., Muders, M. H., Baretton, G. B., Bernhardt, R., Jakob, F. J., Glüer, C., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2362 · Cited by 49
Chinison, J., Aguilar, J. S., Avalos, A., Huang, Y. S., Wang, Z. K., Cameron, D. J., & Hao, J. (2016) · Scientific Reports · doi:10.1038/srep32779 · Cited by 49
Zheng, L., Sun, D.-C., Fan, W., Zhang, Z., Li, Q., & Jiang, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118276 · Cited by 48
Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer
Perry, A. S., O’Hurley, G., Raheem, O. A., Brennan, K., Wong, S. C. K., O’Grady, A., Kennedy, A., Marignol, L. H., Murphy, T. M., Sullivan, L., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27798 · Cited by 46
Xie, Y., Lu, W., Liu, S., Yang, Q., Carver, B. S., Li, E., Wang, Y. Z., Fazli, L., Gleave, M. E., & Chen, Z. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1078 · Cited by 43
Jung, S. J., Oh, S., Lee, G. T., Chung, J., Min, K. S., Yoon, J., Kim, W., Ryu, D. S., Kim, I. Y., & Kang, D. I. (2013) · The World Journal of Men s Health · doi:10.5534/wjmh.2013.31.1.36 · Cited by 43
Genes Upregulated in Prostate Cancer Reactive Stroma Promote Prostate Cancer Progression In Vivo
Dakhova, O., Rowley, D. R., & Ittmann, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1184 · Cited by 40
Lin, C., Lü, W., Zhai, L., Bethea, T. N., Berry, K. L., Qu, Z., Waud, W. R., & Li, Y. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.046 · Cited by 40
Modulating Dickkopf-1: A Strategy to Monitor or Treat Cancer?
Mazon, M., Masi, D., & Carreau, M. (2016) · Cancers · doi:10.3390/cancers8070062 · Cited by 36
SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms
García-Tobilla, P., Solórzano, S. R., Salido-Guadarrama, I., González-Covarrubias, V., Morales-Montor, G., Díaz‐Otañez, C. E., & Rodríguez‐Dorantes, M. (2016) · Gene · doi:10.1016/j.gene.2016.08.030 · Cited by 36
Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis
Lee, S. H., Luong, R. H., Johnson, D. T., Cunha, G. R., Rivina, L., Gonzalgo, M. L., & Sun, Z. (2015) · Oncogene · doi:10.1038/onc.2015.117 · Cited by 34
Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC following Chemotherapy
Kumon, H., Sasaki, K., Ariyoshi, Y., Sadahira, T., Ebara, S., Hiraki, T., Kanazawa, S., Yanai, H., Watanabe, M., & Nasu, Y. (2015) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s23252 · Cited by 34
Kumon, H., Ariyoshi, Y., Sasaki, K., Sadahira, T., Araki, M., Ebara, S., Yanai, H., Watanabe, M., & Nasu, Y. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.53 · Cited by 33
The role of secreted frizzled-related protein 2 expression in prostate cancer
O’Hurley, G., Perry, A. S., O’Grady, A., Loftus, B. M., Smyth, P. C., O’Leary, J. J., Sheils, O. M., Fitzpatrick, J. M., Hewitt, S. M., Lawler, M., et al. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.04073.x · Cited by 29
Yang, Y., Li, J., Hou, J., Xu, C., Wang, L., Yu, Y., Li, Y., Yang, C., Wang, X., & Sun, Y. (2013) · Molecular Biology Reports · doi:10.1007/s11033-013-2506-6 · Cited by 29
Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells
Yang, M., Wang, J., Wang, L., Shen, C., Su, B., Qi, M., Hu, J., Gao, W. Q., Tan, W., & Han, B. (2015) · The Prostate · doi:10.1002/pros.23017 · Cited by 29
Jankú, F., Connolly, R. M., LoRusso, P. M., de Jonge, M., Vaishampayan, U. N., Rodon, J. A., Argilés, G., Myers, A. P., Schmitz, S. H., Ji, Y., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-c45 · Cited by 27
Ghoshal, A., Goswami, U., Sahoo, A. K., Chattopadhyay, A., & Ghosh, S. S. (2015) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5b00305 · Cited by 26
Androgen deprivation modulates gene expression profile along prostate cancer progression
Volante, M., Tota, D., Giorcelli, J., Bollito, E., Napoli, F., Vatrano, S., Buttigliero, C., Molinaro, L., Gontero, P., Porpiglia, F., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.06.004 · Cited by 24
Androgen receptor and prostate cancer
Livermore, K., Munkley, J., & Elliott, D. (2016) · AIMS molecular science · doi:10.3934/molsci.2016.2.280 · Cited by 18
Geng, J., Lin, V. C.-H., Yu, C., Huang, C., Yin, H., Chang, T.-Y., Lu, T., Huang, S., & Bao, B. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121970 · Cited by 18
Valkenburg, K. C., Hostetter, G. H., & Williams, B. O. (2015) · The Prostate · doi:10.1002/pros.23032 · Cited by 16
O'Cearbhaill, R. E., McMeekin, D. S., Mantia-Smaldone, G. M., Gunderson, C. C., Sabbatini, P. J., Cattaruzza, F., Fischer, M. M., Kapoun, A. M., Xu, L., Dupont, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2515 · Cited by 13
Bauman, T. M., Vezina, C. M., Ricke, E. A., Halberg, R. B., Huang, W., Peterson, R. E., & Ricke, W. A. (2016) · Human Pathology · doi:10.1016/j.humpath.2015.12.024 · Cited by 12
Teneggi, V., NG, M. M., Tan, D. S. P., Subbiah, V., Weekes, C. D., Diermayr, V., Ethirajulu, K., Yeo, P., Chen, D., Gan, S., et al. (2016) · Annals of Oncology · doi:10.1016/s0923-7534(21)00310-0 · Cited by 10
ROR1 is an Intriguing Target for Cancer Therapy
Kolb, R. H., Kluz, P., & Zhang, W. (2016) · Molecular Enzymology and Drug Targets · doi:10.21767/2572-5475.10014 · Cited by 4
Cited by
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 616
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Xu, X., Zhang, M., Xu, F., & Jiang, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01276-5 · Cited by 588
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Ulgen, E., Ozisik, O., & Sezerman, O. U. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00858 · Cited by 469
Bone metastasis: mechanisms, therapies, and biomarkers
Clézardin, P., Coleman, R., Puppo, M., Ottewell, P., Bonnelye, E., Paycha, F., Confavreux, C. B., & Holen, I. (2021) · Physiological Reviews · doi:10.1152/physrev.00012.2019 · Cited by 416
Metadata
- Authors
- Murillo-Garzón, V., & Kypta, R.
- Venue
- Nature Reviews Urology
- Published
- 2017-09-12
- Volume
- 14
- Issue
- 11
- Pages
- 683-696
- ISSN
- 1759-4812 (ISSN-L)
- 1759-4820
- OpenAlex
- W2754574141
- Cited by
- 361
- References
- 165
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.